Diabetes in pregnancy: management from preconception to the postnatal period

In April 2025, we reviewed this guideline in relation to hybrid closed loop systems (HCLs) for pregnant populations with type 1 diabetes (T1D).

Surveillance decision

We will update the guideline to include recommendations from NICE's technology appraisal guidance on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

The update will also focus:

• whether to specifically recommend HCLs that are licensed for pregnant populations compared with ‘off-the-shelf’ HCLs for the general population, as the first line treatment for managing T1D in pregnancy.
• the benefit-risk balance of operating HCLs in pregnancy with a lower time in range (TiR) threshold of 3.5 mmol/L blood glucose compared with the currently recommended 4 mmol/L, measured using the capillary method.